title: [Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3 years].
abstract: BACKGROUND
  Three year data collected in the frame of the SOHO study within Spain were used to evaluate antipsychotic treatment outcomes by analyzing remission and relapse as well as the factors influencing them.
  
  
  METHODS
  The SOHO was a prospective, long-term, observational study of the outcomes of schizophrenia treatment in ambulatoty who initiated therapy or who changed to a new antipsychotic drug performed in 10 European countries, with a focus on olanzapine. This article reports the attainment of international schizophrenia clinical remission and relapse criteria and the associated correlates in these patients.
  
  
  CONCLUSIONS
  A total of 2,020 patients were recruited in Spain. Almost 2/3 (60.1%) of the patients met the criteria for clinical remission. Factors that influence the likelihood of remission were identified, such as gender, baseline clinical and/or functional status, time since treatment initiation, treatment with olanzapine versus oral typical antipsychotics, duration of treatment, gender or the need for concomitant anxiolytics. Relapse occurred in 18.7% of patients. Treatment with quetiapine or the prescription of anticholinergics was associated with a greater risk of relapse.
  
  
  CONCLUSIONS
  These results highlight some prognostic factors of the course of schizophrenia and underscore the importance of the antipsychotic choice and its maintenance to achieve favorable long-term clinical outcomes in routine practice.
authors.affiliation: Fundacion San Juan de Dios, Barcelona, Spain. jmharo@comb.es
authors.forename: J M
authors.initials: JM
authors.lastname: Haro
authors.forename: A
authors.initials: A
authors.lastname: Ciudad
authors.forename: J
authors.initials: J
authors.lastname: Alonso
authors.forename: M
authors.initials: M
authors.lastname: Bousoño
authors.forename: D
authors.initials: D
authors.lastname: Suárez
authors.forename: D
authors.initials: D
authors.lastname: Novick
authors.forename: I
authors.initials: I
authors.lastname: Gilaberte
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D000077152:Olanzapine; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction; D012559:Schizophrenia / Q000188:drug therapy / Q000628:therapy*; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine